Details for Patent: 12,582,620

« Back to Dashboard

Which drugs does patent 12,582,620 protect, and when does it expire?

Patent 12,582,620 protects ARYNTA and is included in one NDA.

This patent has eighteen patent family members in seventeen countries.

Summary for Patent: 12,582,620

Title:	Oral solutions comprising lisdexamfetamine salts
Abstract:	Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.
Inventor(s):	Georgios LIOLIOS, Ioannis Psarrakis
Assignee:	Adalvo Ltd
Application Number:	US18/167,634
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 12,582,620

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	ARYNTA	lisdexamfetamine dimesylate	SOLUTION;ORAL	219847-001	Jun 16, 2025		RX	Yes	Yes			Y

International Family Members for US Patent 12,582,620

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020416052
Brazil	112022012986
Canada	3165248